Bm Nat Phos

Dosage for Sodium Phosphate, Dibasic, Heptahydrate varies significantly based on the intended use and the specific product formulation.

Bowel Cleansing (Colonoscopy Prep)

For adult patients undergoing bowel preparation using tablet formulations (such as OsmoPrep), the typical regimen involves a total of 32 tablets (48 grams of sodium phosphate). This is usually administered in a split-dose fashion:

• Evening before procedure: 4 tablets with 8 ounces of clear liquid every 15 minutes for a total of 20 tablets.
• Morning of procedure (3-5 hours prior): 4 tablets with 8 ounces of clear liquid every 15 minutes for a total of 12 tablets.

Hypophosphatemia (Electrolyte Replacement)

When used for phosphorus supplementation, the dose is highly individualized.

• Mild to Moderate: 15-30 mmol of phosphate daily, divided into 2-3 doses.
• Severe: Intravenous replacement may be required at rates of 0.08 to 0.16 mmol/kg over 6 hours, under strict cardiac monitoring.

Sodium Phosphate, Dibasic, Heptahydrate must be used with extreme caution in pediatric populations.

• Bowel Prep: Not generally recommended for children under the age of 18 in the high-dose tablet form due to the risk of electrolyte shifts and renal injury.
• Electrolyte Supplementation: For children with hypophosphatemia, doses are typically calculated by weight (e.g., 0.5 to 1.5 mmol/kg/day).
• Enemas: Pediatric-specific enema formulations exist for children aged 2 to 11, but should only be used under direct medical supervision.

Renal Impairment

Sodium Phosphate, Dibasic, Heptahydrate is contraindicated in patients with significant renal impairment (GFR < 60 mL/min/1.73m²). In patients with mild renal insufficiency, doses must be significantly reduced, and pre-dose/post-dose electrolyte monitoring is mandatory.

Hepatic Impairment

While the liver does not metabolize this salt, patients with hepatic impairment (especially those with cirrhosis and ascites) are at higher risk for fluid shifts and should be monitored closely for volume depletion.

Elderly Patients

Patients over age 65 are at a higher risk for acute phosphate nephropathy. Lower doses or alternative bowel prep agents (such as PEG-based solutions) are often preferred by healthcare providers for this demographic.

• Hydration is Critical: You must drink large volumes of clear liquids (water, clear broth, apple juice) before, during, and after taking this medication to prevent dehydration and kidney damage.
• Tablet Administration: Tablets should be swallowed whole. Do not crush or chew them, as this can alter the absorption rate and cause irritation.
• Timing: For bowel prep, follow the specific hourly schedule provided by your gastroenterologist exactly. Timing is essential for a clear view of the colon.
• Storage: Store at room temperature (20°C to 25°C). Keep the container tightly closed to protect from moisture.

If you miss a dose during a bowel preparation regimen, contact your healthcare provider immediately. Do not double the dose to catch up, as this increases the risk of electrolyte toxicity. Missing doses may result in an incomplete bowel prep, requiring the procedure to be rescheduled.

Signs of overdose include severe muscle cramping, tetany (involuntary muscle contractions), seizures, arrhythmias, and rapid breathing. These are often caused by hypocalcemia (low calcium) resulting from high phosphate levels. If an overdose is suspected, seek emergency medical attention immediately. Treatment typically involves intravenous calcium gluconate and aggressive hydration.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Because Sodium Phosphate, Dibasic, Heptahydrate acts as a potent osmotic agent, most patients will experience gastrointestinal symptoms. These are generally expected as part of the drug's action:

• Bloating and Abdominal Distension: A feeling of fullness or tightness in the stomach as water is drawn into the intestines.
• Nausea: Often occurring shortly after ingestion, especially with liquid formulations.
• Abdominal Cramping: Mild to moderate pain as the intestines contract to move the fluid through.
• Frequent Bowel Movements: This is the intended effect for bowel prep and usually begins within 30 minutes to 3 hours of the first dose.

• Vomiting: If vomiting occurs during bowel prep, it may lead to dehydration and electrolyte loss.
• Dizziness or Lightheadedness: Often a sign of mild dehydration or a drop in blood pressure.
• Headache: Frequently reported, likely due to fluid shifts or caffeine withdrawal (if coffee is avoided during prep).

• Hypocalcemia: Low blood calcium levels, which can cause tingling in the fingers or around the mouth.
• Hyperphosphatemia: Excessively high levels of phosphate in the blood, which can be dangerous for the kidneys.
• Allergic Reactions: Rash, itching, or hives, though these are rare for simple inorganic salts.

> Warning: Stop taking Sodium Phosphate, Dibasic, Heptahydrate and call your doctor immediately if you experience any of these.

• Signs of Kidney Injury: Decreased urine output, swelling in the ankles or feet, or unexplained fatigue. This may indicate acute phosphate nephropathy.
• Cardiac Arrhythmias: A feeling of a racing, fluttering, or skipping heartbeat. Electrolyte imbalances can trigger dangerous heart rhythms, including QT prolongation.
• Seizures: New-onset seizures can occur due to rapid shifts in sodium and calcium levels.
• Severe Dehydration: Extreme thirst, very dark urine, sunken eyes, or fainting.
• Ischemic Colitis: Severe abdominal pain and bloody stools, caused by reduced blood flow to the colon due to fluid shifts.

Sodium Phosphate, Dibasic, Heptahydrate is typically used for short-term procedures. However, repeated use (such as chronic use of phosphate-based laxatives) can lead to:

• Chronic Kidney Disease: Permanent scarring of the kidney tissues (nephrocalcinosis).
• Secondary Hyperparathyroidism: Chronic high phosphate levels can overstimulate the parathyroid glands, leading to bone density loss.
• Electrolyte Dependency: The bowel may become dependent on osmotic stimulants for regular function.

FDA Black Box Warning: Acute Phosphate Nephropathy

Rare but serious cases of acute phosphate nephropathy (a type of acute kidney injury) have been reported in patients using oral sodium phosphate products for bowel cleansing. Some cases resulted in permanent impairment of renal function and required long-term dialysis.

Risk Factors include:

• Age over 55 years.
• Pre-existing kidney disease or decreased renal perfusion.
• Dehydration or low blood volume.
• Use of certain medications (ACE inhibitors, ARBs, NSAIDs, or diuretics).

Report any unusual symptoms to your healthcare provider.

Sodium Phosphate, Dibasic, Heptahydrate is a high-alert medication when used in the large doses required for bowel preparation. It is not a simple "over-the-counter" style laxative when used in these concentrations. Patients must be screened for underlying renal, cardiac, and hepatic conditions before use. Adequate fluid intake is the most critical factor in preventing the most severe complications associated with this drug.

As of 2024, the FDA maintains a strict Black Box Warning for oral sodium phosphate products used for bowel cleansing. The warning emphasizes the risk of Acute Phosphate Nephropathy. This condition involves the deposition of calcium phosphate crystals in the renal tubules, which can lead to sudden and sometimes irreversible kidney failure. Patients must follow the split-dose regimen and hydration instructions exactly to mitigate this risk.

• Allergic Reactions / Anaphylaxis Risk: While rare for the salt itself, Sodium Phosphate, Dibasic, Heptahydrate is often used as a buffer in allergenic extracts. Patients with known hypersensitivity to any component of the formulation should avoid use. Signs of anaphylaxis include difficulty breathing, swelling of the face, and a rapid drop in blood pressure.
• Nephrotoxicity: This is the primary concern. The drug increases the "filtered load" of phosphate in the kidneys. If the patient is dehydrated, the concentration of phosphate in the tubules increases, leading to crystal formation.
• Cardiotoxicity: Electrolyte shifts (specifically low calcium and high phosphate) can affect the electrical conduction of the heart. This is particularly dangerous for patients with a history of heart failure or unstable angina.
• Seizure Risk: Patients with a history of seizures or those taking medications that lower the seizure threshold (like certain antidepressants) are at increased risk due to potential sodium imbalances.

Your healthcare provider may require the following tests before and after administration:

• Basic Metabolic Panel (BMP): To check levels of sodium, potassium, chloride, and bicarbonate.
• Renal Function Tests: Specifically Serum Creatinine and Glomerular Filtration Rate (GFR).
• Serum Calcium and Phosphate: To ensure levels return to the normal range post-procedure.
• Electrocardiogram (ECG): For patients with pre-existing heart conditions or those on medications that affect the QT interval.

While the drug does not have a direct sedative effect, the frequent bowel movements and potential for dizziness or lightheadedness due to fluid shifts mean you should not plan to drive or operate heavy machinery during the bowel preparation process.

Alcohol should be strictly avoided while taking Sodium Phosphate, Dibasic, Heptahydrate. Alcohol is a diuretic and can significantly worsen dehydration, increasing the risk of kidney damage.

For bowel prep, the medication is discontinued once the regimen is complete. If you experience severe vomiting or inability to drink fluids, stop taking the medication and contact your doctor immediately. There is no withdrawal syndrome associated with short-term use, but chronic use must be tapered under medical supervision to avoid rebound constipation.

> Important: Discuss all your medical conditions with your healthcare provider before starting Sodium Phosphate, Dibasic, Heptahydrate.

Certain medications, when combined with Sodium Phosphate, Dibasic, Heptahydrate, create an unacceptable risk of kidney failure:

• Other Osmotic Laxatives: Using multiple phosphate-based products or combining them with other heavy salts can lead to severe electrolyte toxicity.
• Cisapride: The electrolyte shifts caused by sodium phosphate can increase the risk of fatal heart rhythms when taken with drugs like cisapride.

• ACE Inhibitors and ARBs (e.g., Lisinopril, Losartan): These blood pressure medications affect how the kidney handles blood flow. Taking them during bowel prep significantly increases the risk of acute phosphate nephropathy.
• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Diuretics cause fluid loss. Combining them with an osmotic laxative can lead to profound dehydration and renal injury.
• NSAIDs (e.g., Ibuprofen, Naproxen): Non-steroidal anti-inflammatory drugs reduce blood flow to the kidneys. They should be avoided for at least 48 hours before and after taking sodium phosphate bowel prep.

• Digoxin: Shifts in potassium and calcium can increase the risk of digoxin toxicity, leading to heart rhythm disturbances.
• Lithium: Sodium phosphate can affect lithium excretion, potentially leading to toxic lithium levels in the blood.
• Antipsychotics and Antidepressants: Some of these medications can affect the heart's electrical cycle (QT interval), which is further sensitized by electrolyte shifts.

• Dairy Products: High-calcium foods (milk, cheese, yogurt) can bind with phosphate in the gut, reducing the effectiveness of the laxative and potentially causing calcium-phosphate precipitates.
• High-Fat Meals: Can delay gastric emptying and interfere with the timing of the bowel prep.
• Caffeine: While not strictly forbidden, caffeine can contribute to dehydration and should be limited.

• Calcium Supplements: Should be avoided during the prep period as they may interact with the phosphate ions.
• St. John’s Wort: While no direct chemical interaction exists, the GI transit time is so rapid during use that the absorption of any herbal supplement will be effectively zero.

• Inorganic Phosphorus Tests: Levels will be artificially elevated for 24-48 hours after use.
• Calcium Tests: May show temporary hypocalcemia.
• Total CO2/Bicarbonate: May be affected by the buffering nature of the salt.

For each major interaction, the management strategy usually involves temporary discontinuation of the interacting drug (like an ACE inhibitor) for 24-48 hours surrounding the procedure, under a doctor's supervision.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Sodium Phosphate, Dibasic, Heptahydrate must NEVER be used in the following conditions:

• Acute Kidney Injury or Advanced Chronic Kidney Disease: If the GFR is below 60 mL/min, the kidneys cannot clear the phosphate load, leading to certain toxicity.
• Congestive Heart Failure (NYHA Class III or IV): The high sodium load (sodium phosphate contains significant sodium) can cause fluid overload and acute heart failure exacerbation.
• Gastrointestinal Obstruction or Perforation: Using an osmotic laxative against an obstruction can lead to bowel rupture.
• Toxic Megacolon: A severe complication of inflammatory bowel disease where the colon dilates; osmotic agents can cause perforation.
• Biopsy-proven Acute Phosphate Nephropathy: Patients who have previously suffered kidney damage from this drug must never use it again.

• Active Inflammatory Bowel Disease (IBD): In patients with Crohn's or Ulcerative Colitis, the salt can cause mucosal friability that mimics active disease on a colonoscopy.
• History of Seizures: Requires careful monitoring of sodium levels.
• Unstable Angina: The stress of fluid shifts can trigger cardiac events.
• Gastric Bypass Surgery: Altered anatomy can lead to unpredictable absorption and higher risk of electrolyte imbalances.

While Sodium Phosphate is an inorganic salt, patients who have had severe reactions to other phosphate salts (like Potassium Phosphate) may be at risk. Additionally, if the patient is allergic to any preservatives or stabilizers used in the specific commercial formulation (like polyethylene glycol in some tablet binders), the product should be avoided.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Sodium Phosphate, Dibasic, Heptahydrate.

Sodium Phosphate, Dibasic, Heptahydrate is generally categorized as FDA Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. It is unknown whether the high-dose osmotic shifts could affect fetal blood flow or induce preterm labor. Most clinicians prefer PEG-based (polyethylene glycol) solutions for pregnant patients requiring bowel prep, as they do not cause the same degree of electrolyte and fluid shifts. Use during pregnancy should only occur if the potential benefit justifies the risk to the fetus.

It is unknown if sodium phosphate is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants from hypocalcemia or hyperphosphatemia, a decision should be made whether to discontinue nursing or to use an alternative preparation. If used, mothers may choose to "pump and dump" for 24 hours following the procedure.

Safety and efficacy of high-dose oral tablets have not been established in patients under 18 years of age. Pediatric patients are at a much higher risk for dehydration and electrolyte imbalances. For children requiring phosphate supplementation or bowel cleansing, weight-based liquid dosing or pediatric-specific enemas are used, but only under the strict guidance of a pediatric gastroenterologist or nephrologist.

Patients over the age of 65 are at the highest risk for complications. Clinical trials have shown that elderly patients have a higher incidence of serious adverse events, including renal failure and cardiac arrhythmias. This is often due to age-related declines in GFR and a higher likelihood of taking interacting medications like diuretics or ACE inhibitors. For this population, "gentler" prep options are usually the first-line recommendation.

In patients with impaired renal function, the risk of permanent kidney damage is severe. The drug is contraindicated if GFR is < 60. For those with GFR between 60 and 90, extreme caution, lower doses, and pre-procedure hydration are mandatory. This drug is not cleared effectively by peritoneal dialysis and only moderately by hemodialysis.

Patients with cirrhosis or impaired hepatic function may have baseline electrolyte disturbances (like low potassium) that are worsened by sodium phosphate. Furthermore, those with ascites are prone to rapid fluid shifts into the third space, which can lead to intravascular depletion and acute kidney injury (hepatorenal syndrome).

> Important: Special populations require individualized medical assessment.

Sodium Phosphate, Dibasic, Heptahydrate operates primarily through osmotic retention of water. In the intestinal lumen, the dibasic phosphate ($HPO_4^{2-}$) and monobasic phosphate ($H_2PO_4^-$) ions are only partially absorbed. These ions exert an osmotic pull, drawing water from the extracellular space into the bowel. This increases the liquid volume of the stool, softening it and stretching the colon. This stretch activates the myenteric plexus, stimulating peristaltic waves that result in a "purgative" effect.

In its role as a buffer, the dibasic form acts as a weak base that can react with hydrogen ions ($H^+$) to form the monobasic form, thereby stabilizing the pH of pharmaceutical solutions. This is why it is listed in the EPC for allergenic extracts and catecholamines—it ensures the environment remains at a physiological pH (approx. 7.4), preventing the denaturation of proteins or the oxidation of catecholamines.

• Onset of Action: Typically 30 minutes to 3 hours after oral administration.
• Duration of Effect: The purgative effect lasts until the bowel is cleared, usually 4 to 6 hours after the final dose.
• Dose-Response: There is a linear relationship between the dose of phosphate and the volume of water drawn into the bowel, up to a saturation point where no further osmotic effect is achieved but systemic toxicity increases.

| Parameter | Value |

|---|---|

| Bioavailability | 40% - 70% (as phosphate) |

| Protein Binding | Negligible |

| Half-life | 4 - 8 hours (Plasma phosphate) |

| Tmax | 1 - 3 hours |

| Metabolism | None (Inorganic salt) |

| Excretion | Renal (>90%) |

• Molecular Formula: $Na_2HPO_4 \cdot 7H_2O$
• Molecular Weight: 268.07 g/mol
• Solubility: Highly soluble in water; practically insoluble in alcohol.
• Structure: Consists of two sodium cations and one dibasic phosphate anion, associated with seven molecules of water of crystallization. It is an odorless, colorless, or white crystalline solid.

Sodium Phosphate, Dibasic, Heptahydrate is classified as a Saline Laxative and an Electrolyte Replenisher. In the FDA's Established Pharmacologic Class (EPC) system, it is also categorized as a buffering agent within various allergenic extract and vitamin preparations. It is related to other saline laxatives like Magnesium Citrate and Sodium Sulfate.